Side specific differences of tumor budding on non-metastatic colon cancer
N. Sogutcu, S. Gumus, A.Z. Abidin Balkan, H. Bilge, B. Cakabay Department of Pathology, Gazi Yasargil Research and Training Hospital, University of Health Sciences, Diyarbakır, Turkey. seredargumus@hotmail.com
OBJECTIVE: Recent literature suggests that tumor budding (TB) may have a significant clinical impact on colorectal cancers. Our study aims to reveal the effect of TB on the long-term outcomes of patients and to reveal whether there is a difference in tumor location and TB in colonic cancer.
PATIENTS AND METHODS: A cohort of 100 patients with non-metastatic colon cancer was included in the study. The clinicopathological information of the patients was reviewed. Patients’ preparations were re-evaluated to identify TB as: low, medium, and high and represent 0-4 buds, 5-9 buds, and 10 or more buds per 0.785 mm2, respectively. Long-term oncological outcomes of patients were analyzed. The recurrence, metastasis, and final status of the patients were determined during the follow-up period.
RESULTS: Low TN was associated with <65 year (p = 0.048), absence of lymphatic metastasis (p = 0.003), and absence of perineural invasion (p = 0.023). High TB was associated with higher pT stage (p = 0.017) and tumor stage (p = 0.005). Additionally, right-sided tumors had a high TB score than left side (82.3% vs. 23.6%, p = 0.011). Patients with high TB had lower overall survival, but these were not statically significant. According to multiple regression analysis, mortality risk was associated with age (p = 0.046), pN status (p = 0.003) and TB (p = 0.040).
CONCLUSIONS: High TB is associated with mortality in colon cancer and is more common in right colonic carcinoma.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
N. Sogutcu, S. Gumus, A.Z. Abidin Balkan, H. Bilge, B. Cakabay
Side specific differences of tumor budding on non-metastatic colon cancer
Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 20
Pages: 7649-7655
DOI: 10.26355/eurrev_202210_30041